508 filings
Page 5 of 26
CORRESP
9mnwcq2c4jax
5 Jan 23
Correspondence with SEC
12:00am
CORRESP
ow2izbm7k84i tgc9c2v
5 Jan 23
Correspondence with SEC
12:00am
8-K
ups45rkde1oey t6
4 Jan 23
OpGen Announced 1-for-20 Reverse Stock Split
4:48pm
CORRESP
0wiydh0ys8kd57z3
30 Dec 22
Correspondence with SEC
12:00am
UPLOAD
tyonts1
29 Dec 22
Letter from SEC
12:00am
UPLOAD
4f3pj yth6p2xirp
21 Dec 22
Letter from SEC
12:00am
CORRESP
z77gu1rmtz 5h2p81
21 Dec 22
Correspondence with SEC
12:00am
CORRESP
heb90zlh5a6z3 o33
16 Dec 22
Correspondence with SEC
12:00am
UPLOAD
fja2n
15 Dec 22
Letter from SEC
12:00am
8-K
pmg8nutryp732
13 Dec 22
OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel
4:28pm
8-K
qetxlp
30 Nov 22
Submission of Matters to a Vote of Security Holders
4:31pm
8-K
u2nubh v6s
10 Nov 22
OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update
4:19pm
DEFA14A
bz5um 8esqc
17 Oct 22
Additional proxy soliciting materials
4:20pm
D
uunqobv
11 Oct 22
$3.38 mm in equity / options, sold $3.38 mm, 1 investor
9:02pm
8-K
9llqh50z8yiej
3 Oct 22
OpGen Announces $3.38 Million Registered Direct Offering
5:16pm